RhoC GTPase Overexpression Modulates Induction of Angiogenic Factors in Breast Cells

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2001 Feb 24

PMID 11191108

Citations 52

Authors

K L van Golen

Z F Wu

X T Qiao

L Bao

S D Merajver

Affiliations

Soon will be listed here.

Abstract

Inflammatory breast cancer (IBC) is a distinct and aggressive form of locally advanced breast cancer. IBC is highly angiogenic, invasive, and metastatic at its inception. Previously, we identified specific genetic alterations of IBC that contribute to this highly invasive phenotype. RhoC GTPase was overexpressed in 90% of archival IBC tumor samples, but not in stage-matched, non-IBC tumors. To study the role of RhoC GTPase in contributing to an IBC-like phenotype, we generated stable transfectants of human mammary epithelial cells overexpressing the RhoC gene, and studied the effect of RhoC GTPase overexpression on the modulation of angiogenesis in IBC. Levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), interleukin-6 (IL-6), and interleukin-8 (IL-8) were significantly higher in the conditioned media of the HME-RhoC transfectants than in the untransfected HME and HME-beta-galactosidase control media, similar to the SUM149 IBC cell line. Inhibition of RhoC function by introduction of C3 exotransferase decreased production of angiogenic factors by the HME-RhoC transfectants and the SUM149 IBC cell line, but did not affect the control cells. These data support the conclusion that overexpression of RhoC GTPase is specifically and directly implicated in the control of the production of angiogenic factors by IBC cells.

Citing Articles

Angiogenesis, a key point in the association of gut microbiota and its metabolites with disease.

Wang Y, Bai M, Peng Q, Li L, Tian F, Guo Y Eur J Med Res. 2024; 29(1):614.

PMID: 39710789 PMC: 11664877. DOI: 10.1186/s40001-024-02224-5.

RhoC in association with TET2/WDR5 regulates cancer stem cells by epigenetically modifying the expression of pluripotency genes.

Thomas P, Srivastava S, Udayashankara A, Damodaran S, Yadav L, Mathew B Cell Mol Life Sci. 2022; 80(1):1.

PMID: 36469134 PMC: 11073244. DOI: 10.1007/s00018-022-04645-z.

Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones.

Morrow R, Allam A, Yeo B, Deb S, Murone C, Lim E Cancers (Basel). 2022; 14(9).

PMID: 35565421 PMC: 9105876. DOI: 10.3390/cancers14092292.

Pathological and molecular characteristics of inflammatory breast cancer.

di Bonito M, Cantile M, Botti G Transl Cancer Res. 2022; 8(Suppl 5):S449-S456.

PMID: 35117122 PMC: 8798351. DOI: 10.21037/tcr.2019.03.24.

RhoC Modulates Cell Junctions and Type I Interferon Response in Aggressive Breast Cancers.

Abraham H, Ulintz P, Goo L, Yates J, Little A, Bao L Front Oncol. 2021; 11:712041.

PMID: 34513691 PMC: 8428533. DOI: 10.3389/fonc.2021.712041.

References

van Golen K, Wu Z, Qiao X, Bao L, Merajver S . RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000; 60(20):5832-8. View

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View

Danielsen T, Rofstad E . VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts. Int J Cancer. 1998; 76(6):836-41. DOI: 10.1002/(sici)1097-0215(19980610)76:6<836::aid-ijc12>3.0.co;2-0. View

Aktories K . Rho proteins: targets for bacterial toxins. Trends Microbiol. 1997; 5(7):282-8. DOI: 10.1016/S0966-842X(97)01067-6. View

Mizuno K, Sone S, Orino E, Mukaida N, Matsushima K, Ogura T . Spontaneous production of interleukin-8 by human lung cancer cells and its augmentation by tumor necrosis factor alpha and interleukin-1 at protein and mRNA levels. Oncology. 1994; 51(5):467-71. DOI: 10.1159/000227385. View

Chotani M, Touhalisky K, Chiu I . The small GTPases Ras, Rac, and Cdc42 transcriptionally regulate expression of human fibroblast growth factor 1. J Biol Chem. 2000; 275(39):30432-8. DOI: 10.1074/jbc.M003545200. View

Kozawa O, Tokuda H, Matsuno H, Uematsu T . Involvement of p38 mitogen-activated protein kinase in basic fibroblast growth factor-induced interleukin-6 synthesis in osteoblasts. J Cell Biochem. 1999; 74(3):479-85. View

Harper M, Goddard L, Mathews P, Nicholson R . Expression of androgen receptor and growth factors in premalignant lesions of the prostate. J Pathol. 1999; 186(2):169-77. DOI: 10.1002/(SICI)1096-9896(1998100)186:2<169::AID-PATH164>3.0.CO;2-W. View

Cohen T, Nahari D, Cerem L, Neufeld G, Levi B . Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996; 271(2):736-41. DOI: 10.1074/jbc.271.2.736. View

10.

Mukhopadhyay D, Tsiokas L, Sukhatme V . Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 1995; 55(24):6161-5. View

11.

Wang D, Huang H, Kazlauskas A, Cavenee W . Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res. 1999; 59(7):1464-72. View

12.

Okada F, Rak J, Croix B, Lieubeau B, Kaya M, Roncari L . Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A. 1998; 95(7):3609-14. PMC: 19883. DOI: 10.1073/pnas.95.7.3609. View

13.

Miller L, Kurtzman S, Wang Y, Anderson K, LINDQUIST R, Kreutzer D . Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res. 1998; 18(1A):77-81. View

14.

Volm M, Koomagi R, Mattern J, Stammler G . Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Res. 1997; 17(1A):99-103. View

15.

Fidler I, Kumar R, Bielenberg D, Ellis L . Molecular determinants of angiogenesis in cancer metastasis. Cancer J Sci Am. 1998; 4 Suppl 1:S58-66. View

16.

Folkman J . Angiogenesis inhibitors generated by tumors. Mol Med. 1995; 1(2):120-2. PMC: 2229937. View

17.

Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O . Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem. 1994; 269(9):6271-4. View

18.

Warny M, Keates A, Keates S, Castagliuolo I, Zacks J, Aboudola S . p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest. 2000; 105(8):1147-56. PMC: 300827. DOI: 10.1172/JCI7545. View

19.

Rodeck U, Becker D, Herlyn M . Basic fibroblast growth factor in human melanoma. Cancer Cells. 1991; 3(8):308-11. View

20.

van Golen K, Davies S, Wu Z, Wang Y, Bucana C, Root H . A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res. 1999; 5(9):2511-9. View